Local Coverage Determinations (LCD) Summary Providers: If you wish to obtain the full text of the LCDs (and articles) described in this section, they are available on the Empire Medicare Services Web site at http://www.empiremedicare.com/PartA/ parta_lcd.cfm. Read and accept the CPT License for Use, then click on the “Policies in Notice Period” link or write to: Empire Medicare Services Or call the Empire Medicare Services Provider Inquiries Department at: To receive notification when new policies or updates are posted to our Web site, subscribe to the Empire Medicare Services Local Coverage Determination (LCD) mailing list from the EMS Web site at: http://www.empiremedicare.com/PartA/parta_lcd.cfm. Just read and accept the CPT License for Use, click on the appropriate “subscribe to mailing list” link and fill in the requested information. Local Coverage Determination The Local Coverage Determination (LCD) identified below will be effective April 17, 2006. Beta Glucocerebrosidase and Analogues - L2206 Notice Period: 03/01/2006 - 04/16/2006 LCD Description: Gaucher Disease is a rare, inherited, and potentially fatal disease that involves the accumulation of the lipid glucocerebroside in the lysosomes of the monocyte macrophage system. This causes the displacement of normal cells in the bone marrow, hepatosplenomegaly, organ dysfunction, anemia, thrombocytopenia, and skeletal damage. As a result, the symptoms may include abdominal swelling, incapacitating bone pain, and restricted mobility, which is the major cause of disability in adult patients with this condition. Beta glucocerebrosidase (Ceredase®) has been shown to be effective in reversing the course of the disease. Replacement therapy is palliative in Gaucher’s disease and does not correct the underlying genetic abnormality. Therefore, the therapy must be continued indefinitely. There are three types of Gaucher Disease which include:
Analogues |
